Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Welt, Tobiasa; * | Kulic, Lukaa; d | Hoey, Sarah E.a | McAfoose, Jordana | Späni, Claudiaa | Chadha, Antonella Santuccionec | Fisher, Abrahamb | Nitsch, Roger M.a
Affiliations: [a] Division of Psychiatry Research, University of Zürich Campus Schlieren, Switzerland | [b] Israel Institute for Biological Research, Ness-Ziona, Israel | [c] Swiss Agency for Therapeutic Products, Bern, Switzerland | [d] Center for Integrative Human Physiology (ZIHP), University of Zurich, Switzerland
Correspondence: [*] Correspondence to: Tobias Welt, MD, Division of Psychiatry Research, University of Zürich, Wagistrasse 12, 8952 Schlieren, Switzerland. Tel.: +41 44 634 8848/79 800 9816; Fax: +41 634 8876; [email protected]
Abstract: Indirect modulation of cholinergic activity by cholinesterase inhibition is currently a widely established symptomatic treatment for Alzheimer’s disease (AD). Selective activation of certain muscarinic receptor subtypes has emerged as an alternative cholinergic-based amyloid-lowering strategy for AD, as selective muscarinic M1 receptor agonists can reduce amyloid-β (Aβ) production by shifting endoproteolytic amyloid-β protein precursor (AβPP) processing toward non-amyloidogenic pathways. In this study, we addressed the hypothesis that acute stimulation of muscarinic M1 receptors can inhibit Aβ production in awake and freely moving AβPP transgenic mice. By combining intracerebral microdialysis with retrodialysis, we determined hippocampal Aβ concentrations during simultaneous pharmacological modulation of brain M1 receptor function. Infusion with a M1 receptor agonist AF102B resulted in a rapid reduction of interstitial fluid (ISF) Aβ levels while treatment with the M1 antagonist dicyclomine increased ISF Aβ levels reaching significance within 120 minutes of treatment. The reduction in Aβ levels was associated with PKCα and ERK activation resulting in increased levels of the α-secretase ADAM17 and a shift in AβPP processing toward the non-amyloidogenic processing pathway. In contrast, treatment with the M1 receptor antagonist dicyclomine caused a decrease in levels of phosphorylated ERK that was independent of PKCα, and led to an elevation of β-secretase levels associated with increased amyloidogenic AβPP processing. The results of this study demonstrate rapid effects of in vivo M1 receptor modulation on the ISF pool of Aβ and suggest that intracerebral microdialysis with retrodialysis is a useful technical approach for monitoring acute treatment effects of muscarinic receptor modulators on AβPP/Aβ metabolism.
Keywords: AβPP processing, AβPP transgenic mice, Alzheimer’s disease, amyloid-β, microdialysis, muscarinic acetylcholine receptor
DOI: 10.3233/JAD-150152
Journal: Journal of Alzheimer's Disease, vol. 46, no. 4, pp. 971-982, 2015
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]